The University of Chicago Header Logo

Connection

Sarah E. Cobey to Humans

Back to Details
This is a "connection" page, showing publications Sarah E. Cobey has written about Humans.
Sarah E. Cobey
Connection Strength
0.845
Humans
  1. Reduced Effectiveness of Repeat Influenza Vaccination: Distinguishing Among Within-Season Waning, Recent Clinical Infection, and Subclinical Infection. J Infect Dis. 2024 Dec 16; 230(6):1309-1318.
    View in: PubMed
    Score: 0.032
  2. Measures of Population Immunity Can Predict the Dominant Clade of Influenza A (H3N2) in the 2017-2018 Season and Reveal Age-Associated Differences in Susceptibility and Antibody-Binding Specificity. Influenza Other Respir Viruses. 2024 11; 18(11):e70033.
    View in: PubMed
    Score: 0.031
  3. Preliminary Findings From the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: A Randomized Controlled Trial. Clin Infect Dis. 2024 Oct 15; 79(4):901-909.
    View in: PubMed
    Score: 0.031
  4. Vaccination against rapidly evolving pathogens and the entanglements of memory. Nat Immunol. 2024 Nov; 25(11):2015-2023.
    View in: PubMed
    Score: 0.031
  5. A speed limit on serial strain replacement from original antigenic sin. Proc Natl Acad Sci U S A. 2024 Jun 18; 121(25):e2400202121.
    View in: PubMed
    Score: 0.030
  6. Investigation of the Impact of Childhood Immune Imprinting on Birth Year-Specific Risk of Clinical Infection During Influenza A Virus Epidemics in Hong Kong. J Infect Dis. 2023 07 14; 228(2):169-172.
    View in: PubMed
    Score: 0.029
  7. The Potential Beneficial Effects of Vaccination on Antigenically Evolving Pathogens. Am Nat. 2022 02; 199(2):223-237.
    View in: PubMed
    Score: 0.026
  8. Of variants and vaccines. Cell. 2021 12 22; 184(26):6222-6223.
    View in: PubMed
    Score: 0.026
  9. Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality. Nat Med. 2021 08; 27(8):1321-1323.
    View in: PubMed
    Score: 0.025
  10. Lineage-specific protection and immune imprinting shape the age distributions of influenza B cases. Nat Commun. 2021 07 14; 12(1):4313.
    View in: PubMed
    Score: 0.025
  11. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nat Rev Immunol. 2021 05; 21(5):330-335.
    View in: PubMed
    Score: 0.024
  12. Earliest infections predict the age distribution of seasonal influenza A cases. Elife. 2020 07 07; 9.
    View in: PubMed
    Score: 0.023
  13. Modeling infectious disease dynamics. Science. 2020 May 15; 368(6492):713-714.
    View in: PubMed
    Score: 0.023
  14. Age-specific differences in the dynamics of protective immunity to influenza. Nat Commun. 2019 04 10; 10(1):1660.
    View in: PubMed
    Score: 0.021
  15. Repeated Vaccination May Protect Children From Influenza Infection. JAMA Netw Open. 2018 10 05; 1(6):e183730.
    View in: PubMed
    Score: 0.021
  16. Estimating Vaccine-Driven Selection in Seasonal Influenza. Viruses. 2018 09 18; 10(9).
    View in: PubMed
    Score: 0.020
  17. Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012-2013. Clin Infect Dis. 2018 07 18; 67(3):327-333.
    View in: PubMed
    Score: 0.020
  18. Characterization of the immunologic repertoire: A quick start guide. Immunol Rev. 2018 07; 284(1):5-8.
    View in: PubMed
    Score: 0.020
  19. Selection and Neutral Mutations Drive Pervasive Mutability Losses in Long-Lived Anti-HIV B-Cell Lineages. Mol Biol Evol. 2018 05 01; 35(5):1135-1146.
    View in: PubMed
    Score: 0.020
  20. Host population structure and treatment frequency maintain balancing selection on drug resistance. J R Soc Interface. 2017 08; 14(133).
    View in: PubMed
    Score: 0.019
  21. Does influenza drive absolute humidity? Proc Natl Acad Sci U S A. 2017 03 21; 114(12):E2270-E2271.
    View in: PubMed
    Score: 0.018
  22. Immune history and influenza virus susceptibility. Curr Opin Virol. 2017 02; 22:105-111.
    View in: PubMed
    Score: 0.018
  23. Limits to Causal Inference with State-Space Reconstruction for Infectious Disease. PLoS One. 2016; 11(12):e0169050.
    View in: PubMed
    Score: 0.018
  24. Explaining the geographical origins of seasonal influenza A (H3N2). Proc Biol Sci. 2016 09 14; 283(1838).
    View in: PubMed
    Score: 0.018
  25. The evolution within us. Philos Trans R Soc Lond B Biol Sci. 2015 Sep 05; 370(1676).
    View in: PubMed
    Score: 0.017
  26. Trade-offs in antibody repertoires to complex antigens. Philos Trans R Soc Lond B Biol Sci. 2015 Sep 05; 370(1676).
    View in: PubMed
    Score: 0.017
  27. Pathogen evolution and the immunological niche. Ann N Y Acad Sci. 2014 Jul; 1320:1-15.
    View in: PubMed
    Score: 0.015
  28. Pathogen diversity and hidden regimes of apparent competition. Am Nat. 2013 Jan; 181(1):12-24.
    View in: PubMed
    Score: 0.014
  29. Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes. Science. 2012 Mar 16; 335(6074):1376-80.
    View in: PubMed
    Score: 0.013
  30. Consequences of host heterogeneity, epitope immunodominance, and immune breadth for strain competition. J Theor Biol. 2011 Feb 07; 270(1):80-7.
    View in: PubMed
    Score: 0.012
  31. Ecological factors driving the long-term evolution of influenza's host range. Proc Biol Sci. 2010 Sep 22; 277(1695):2803-10.
    View in: PubMed
    Score: 0.011
  32. The role of viral interaction in household transmission of symptomatic influenza and respiratory syncytial virus. Nat Commun. 2025 Feb 01; 16(1):1249.
    View in: PubMed
    Score: 0.008
  33. Predicting pathogen mutual invasibility and co-circulation. Science. 2024 Oct 11; 386(6718):175-179.
    View in: PubMed
    Score: 0.008
  34. High-throughput sequencing-based neutralization assay reveals how repeated vaccinations impact titers to recent human H1N1 influenza strains. J Virol. 2024 Oct 22; 98(10):e0068924.
    View in: PubMed
    Score: 0.008
  35. Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med. 2023 Jun; 29(6):1520-1529.
    View in: PubMed
    Score: 0.007
  36. Tracking changes in SARS-CoV-2 transmission with a novel outpatient sentinel surveillance system in Chicago, USA. Nat Commun. 2022 09 22; 13(1):5547.
    View in: PubMed
    Score: 0.007
  37. COVID-19 and children. Science. 2022 09 09; 377(6611):1144-1149.
    View in: PubMed
    Score: 0.007
  38. PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2. mSphere. 2022 06 29; 7(3):e0017922.
    View in: PubMed
    Score: 0.007
  39. SARS-CoV-2 Infection Among Pregnant People at Labor and Delivery and Changes in Infection Rates in the General Population: Lessons Learned From Illinois. Public Health Rep. 2022 Jul-Aug; 137(4):672-678.
    View in: PubMed
    Score: 0.007
  40. Improvements in Severe Acute Respiratory Syndrome Coronavirus 2 Testing Cascade in the United States: Data From Serial Cross-sectional Assessments. Clin Infect Dis. 2022 05 03; 74(9):1534-1542.
    View in: PubMed
    Score: 0.007
  41. Incorporating temporal distribution of population-level viral load enables real-time estimation of COVID-19 transmission. Nat Commun. 2022 03 03; 13(1):1155.
    View in: PubMed
    Score: 0.007
  42. Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India. Nat Med. 2022 05; 28(5):934-938.
    View in: PubMed
    Score: 0.006
  43. An Egg-Derived Sulfated N-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines. mBio. 2021 06 29; 12(3):e0083821.
    View in: PubMed
    Score: 0.006
  44. Geographic and demographic heterogeneity of SARS-CoV-2 diagnostic testing in Illinois, USA, March to December 2020. BMC Public Health. 2021 06 10; 21(1):1105.
    View in: PubMed
    Score: 0.006
  45. Investigate the origins of COVID-19. Science. 2021 05 14; 372(6543):694.
    View in: PubMed
    Score: 0.006
  46. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021 02 26; 371(6532):916-921.
    View in: PubMed
    Score: 0.006
  47. Practical considerations for measuring the effective reproductive number, Rt. PLoS Comput Biol. 2020 12; 16(12):e1008409.
    View in: PubMed
    Score: 0.006
  48. Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans. Sci Transl Med. 2020 12 09; 12(573).
    View in: PubMed
    Score: 0.006
  49. Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines During the 2017-2018 Season. Clin Infect Dis. 2020 09 12; 71(6):1447-1453.
    View in: PubMed
    Score: 0.006
  50. Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility. Nat Commun. 2020 09 11; 11(1):4566.
    View in: PubMed
    Score: 0.006
  51. Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals. Cell Host Microbe. 2019 03 13; 25(3):357-366.e6.
    View in: PubMed
    Score: 0.005
  52. Spec-seq unveils transcriptional subpopulations of antibody-secreting cells following influenza vaccination. J Clin Invest. 2019 01 02; 129(1):93-105.
    View in: PubMed
    Score: 0.005
  53. Use of an individual-based model of pneumococcal carriage for planning a randomized trial of a whole-cell vaccine. PLoS Comput Biol. 2018 10; 14(10):e1006333.
    View in: PubMed
    Score: 0.005
  54. Recurring infection with ecologically distinct HPV types can explain high prevalence and diversity. Proc Natl Acad Sci U S A. 2017 12 19; 114(51):13573-13578.
    View in: PubMed
    Score: 0.005
  55. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A. 2017 11 21; 114(47):12578-12583.
    View in: PubMed
    Score: 0.005
  56. Viral factors in influenza pandemic risk assessment. Elife. 2016 11 11; 5.
    View in: PubMed
    Score: 0.005
  57. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses. 2013 Sep; 7 Suppl 2:52-53.
    View in: PubMed
    Score: 0.004
  58. Anticipating the species jump: surveillance for emerging viral threats. Zoonoses Public Health. 2012 May; 59(3):155-63.
    View in: PubMed
    Score: 0.003
  59. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses. 2012 Mar; 6(2):142-52, e1-5.
    View in: PubMed
    Score: 0.003
  60. Strength and tempo of selection revealed in viral gene genealogies. BMC Evol Biol. 2011 Jul 25; 11:220.
    View in: PubMed
    Score: 0.003
  61. Predicting the epidemic sizes of influenza A/H1N1, A/H3N2, and B: a statistical method. PLoS Med. 2011 Jul; 8(7):e1001051.
    View in: PubMed
    Score: 0.003
  62. Global migration dynamics underlie evolution and persistence of human influenza A (H3N2). PLoS Pathog. 2010 May 27; 6(5):e1000918.
    View in: PubMed
    Score: 0.003
  63. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science. 2006 Dec 22; 314(5807):1898-903.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.